Skip Navigation


NDT Advance Access originally published online on April 9, 2008
Nephrology Dialysis Transplantation 2008 23(7):2409-2411; doi:10.1093/ndt/gfn194
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow All Versions of this Article:
23/7/2409    most recent
gfn194v2
gfn194v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by A., H. J.
Right arrow Articles by Vaidya, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by A., H. J.
Right arrow Articles by Vaidya, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Acute renal failure secondary to oxalosis in a recipient of a simultaneous kidney–pancreas transplant: was mycophenolate the cause?

Hamidian Jahromi A.1, Ian S. D. Roberts2, Chris G. Winearls3 and Anil Vaidya3

1 Renal Transplant Unit, St George's Hospital, London 2 Department of Cellular Pathology, John Radcliffe Hospital 3 Oxford Transplant Centre, Churchill Hospital, Oxford, UK

Correspondence and offprint requests to: Hamidian Jahromi A., Renal Transplant Unit, St. George's Hospital, London SW17 0QT, UK. Or First Floor Flat, 30 Edith Road, Kensington, London W14 9BB, UK. E-mail: alirezahamidian@yahoo.com

Keywords: hyperoxalosis; mycophenolate mofetil; pancreas and kidney; renal failure

The first 10% of the full text of this article appears below.

Mycophenolate mofetil (MMF) is now the preferred antimetabolite for post-transplant immunosuppression [1]. Although leucopenia and diarrhoea are the main side effects, there are case reports of a malabsorption syndrome caused by MMF [2].

Oxalosis, either primary or secondary, is a well-recognised cause for renal failure. Secondary hyperoxaluria is caused by increased intestinal oxalate absorption and can be aggravated by excessive dietary oxalate intake. Particular gastro-intestinal disorders such as short bowel syndrome, chronic inflammatory bowel disease and fat malabsorption syndromes, e.g. chronic pancreatitis, are known to increase the risk of secondary hyperoxaluria [3]. Oxalosis causing renal allograft failure has also . . . [Full Text of this Article]



   Case history
 


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A.-L. Hiel, M. Tintillier, C. Cuvelier, A. Leonard, and J.-M. Pochet
Acute renal failure secondary to oxalosis in a recipient of a simultaneous kidney-pancreas transplant: was mycophenolate the cause?
Nephrol. Dial. Transplant., January 1, 2009; 24(1): 326 - 326.
[Full Text] [PDF]